Esperite (voorheen Cryo Save) « Terug naar discussie overzicht

Aankoop patent eiwitcomplexen immunologie

257 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 » | Laatste
DeZwarteRidder
0
quote:

cqtvld schreef op 26 augustus 2015 08:07:

Op een ander forum hebben we afgesproken om niet meer te reageren op deze persoon, wij hebben nu geen last meer van hem .Deal.Voor de rest allemaal succes.
Welk forum is dat...???
Of durf je dat niet te vertellen...??
[verwijderd]
0
-24 cent
over een paar weken is dit een pennystock
bedankt Amar dat je de boel weer hebt belazerd, maar je zal er niet mee zitten
Tiekoes1
0
sportliefhebber
0
quote:

Vitavita schreef op 17 oktober 2015 17:02:

kom deze tegen:

www.presspeople.com/nota/uso-exomas-d...
AB
Mooi bericht en goed gevonden.
Waar Bing al niet goed voor is...
torro
0
Met behulp van exome afkomstige stamcellen en hun medische toepassingen.

Vrijdag 16 oktober, 2015, 09:52Door Cryo-Cord

Een jaar geleden, uit Chili de vroege ontwikkeling van een behandeling voor het aankondigen voorkomen hersenverlamming gebruiken exome uit mesenchymale stamcellen.

Hersenverlamming veroorzaakt door permanente schade aan de hersenen die eerder heeft plaatsgevonden, tijdens of na de bevalling. De ontwikkeling doel was om een behandeling die de referentie-regeneratie van hersengebieden eerder getroffen dan alleen de behandeling van de symptomen als gevolg van deze blessures beïnvloedt bieden.
In dezelfde geest, in 2015, CryoSave (Crio-Cord in Spanje), de bank de biologische Esperite Group, reeds een behandeling voor de ziekte bij 7 kinderen die hun hadden stamcellen gecryopreserveerd in de celbank. In dit geval hebben we gebruik gemaakt van stamcellen uit het bloed en navelstrengweefsel.
Na deze stappen heeft Esperite een nieuwe stap voorwaarts voor zover stamcel behandelingen betreft genomen. De groep heeft net de rechten van een internationaal octrooi voor het gebruik van exoom van mesenchymale stamcellen in gebruik bij de behandeling van ontstekings- en auto-immuunziekten.

Deze extracellulaire blaasjes genaamd exome, waarvan de belangrijkste missie is om de communicatie tussen cellen te vergemakkelijken. Bovendien reguleren ze celprocessen door immuuncellen (vooral lymfocyten B).
Tot nu toe zijn exoom klinisch toegepast (vooral belangrijk in kankerdiagnose) biologische markers en drugs vervoeren naar specifieke gebieden, waardoor de noodzakelijke dosis verminderen daarvan en dus de bijwerkingen te verminderen.
Door het opnemen van dit gebruik van de regeneratieve geneeskunde exome, zal combineren die eigenschappen immunomodulerende middelen en het regeneratievermogen van mesenchymale cellen.

Dus met dit octrooi kan worden behandeld ontstekingsziekten zoals reumatoïde artritis en andere bindweefsel, ziekte van Crohn of type 1 diabetes onder anderen. Maar ook toepassing bij de preventie van transplantaatafstoting vinden, aangezien het exoom stimuleert het proces van tolerantie en vermindering van de immuunrespons.
Het octrooi voor deze technologie werd ontwikkeld aan de Bambino Gesù ziekenhuis in Rome en eerste klinische applicatie in acute inflammatoire neurologische aandoeningen en anderen, zoals ruggenmergletsel, hersenletsel of neonatale e
torro
0
Maar ook toepassing bij de preventie van transplantaatafstoting vinden, aangezien het exoom stimuleert het proces van tolerantie en vermindering van de immuunrespons.
Het octrooi voor deze technologie werd ontwikkeld aan de Bambino Gesù ziekenhuis in Rome en eerste klinische applicatie in acute inflammatoire neurologische aandoeningen en anderen, zoals ruggenmergletsel, hersenletsel of neonatale encefalopathie, zal het eerste onderzoek zijn.
Vitavita
0
quote:

tiekoes1 schreef op 9 maart 2016 11:40:

Lees ook even in de telegraaf beurs goeroes Robert Schuckink kool.
...jammer, dat Esperite niet genoemd wordt..
Jeanette
0
Vitavita
0
Esperite (ESP) leads international consortium for clinical translation of extracellular vesicles use in various therapies
September 30, 2016

Extracellular vesicles (EVs) disruptive technology targets unmet needs in neuroinflammatory diseases at lower costs than allogenic stem cell therapies.

Esperite’s business unit The Cell Factory develops EVs-based therapeutics in treatment of drug-resistant epilepsy in children jointly with Bambino Gesu` Children’s Hospital, Mario Negri Institute for Pharmacological Research and the Women’s and Children’s Health Department of the University of Padua.

Esperite N.V. (Euronext: ESP, “Esperite”) sponsors an international consortium of the leading teams in paediatric regenerative medicine to bring extracellular vesicles (EVs) technology to the clinic with niche applications in treatment of severe neuro-inflammatory diseases. Its first project focuses on EVs application in untreatable-yet acute and chronic drug-resistant epilepsy in children. The consortium will also investigate EVs and exosomes characteristics, potency, and a mode of action and will further improve the EVs production processes.

Led by Professor Federico Vigevano at Bambino Gesu` Children’s Hospital with Dr Alessandra Fierabracci providing her expertise in Immunology and Dr. Annamaria Vezzani at Mario Negri Institute, pre-clinical tests of mesenchymal stem cells (MSC)-derived EVs are underway to confirm the safety and efficacy already demonstrated in multiple in vitro and in vivo models. This project will enable the first-in-man use of MSC-derived EVs and exosomes in treatment of drug-resistant epilepsy in children. The project follows a long-term collaboration between the Children’s Hospital and the Esperite group initiated and liaised by Professor Stefano Grossi, Esperite’s Scientific Director in Italy.

In parallel, Esperite’s regenerative medicine division, The Cell Factory, in partnership with Professor Maurizio Muraca’s team at University of Padua, are better characterising EVs to establish clinical grade standards for production, purification, quantification, bio-distribution and molecular characterisation of new EV-based therapeutics.

Professor Muraca has also agreed to join the Scientific Board of The Cell Factory to support EVs products development and clinical translation. Professor Muraca has extensive and long-term experience in immunology, EVs and MSCs research, and the expertise in regulations of advanced therapies use in clinic.

The Cell Factory produces ultra-pure EVs and exosomes according to GLP/GMP guidelines, using proprietary technology for expansion of MSC in fully defined media with no use of animal-derived components at any stage. Stem cells expansion is performed in the most efficient and scalable 3D culture systems using microcarrier beads. The Cell Factory’s proprietary closed cell culture system produces high purity EVs and exosomes using pharmaceutical-quality sequential filtration system for EVs extraction and purification. The system can be easily scaled up improving significantly EVs production costs, footprint and process scalability. EVs products can be manufactured with this technology at least 10x more efficiently and cheaper when comparing to MSC equivalent.

The consortium will investigate the anti-inflammatory and anti-epileptic effect of the “off-the-shelf” EVs derived from non-HLA-matched MSC lines. The advantages of using EVs in treatment of acute and chronic epilepsy are product stability and low production costs providing the “off-the-shelf” drug for immediate and repeated non-invasive application. In a broader perspective, the positive results of using immunosuppressive EVs in a central nervous system would open up a possibility of immediate intervention in acute diseases in neurology such as stroke, traumatic brain, spinal cord injury, newborn hypoxic ischemia and many others.

Diseases of central nervous system are among most devastating for patients and their relatives. Neurological disorders are generating a significant additional cost related to hospitalisation, rehabilitation, often eliminate the patients and their relatives from a job market. CDC estimated that annual costs related to epilepsy exceeds 15 billion USD in the United States alone with 50 million patients worldwide (WHO). Cost related to brain stroke in the United States is estimated to 34 billion USD per year (CDC), with 15 million new patients worldwide each year (WHO). Cumulative cost related to traumatic brain injury (TBI) and spinal cost injury in the United States is over 80 billion USD per year (CDC and AANS), with up to 0.5 million new incidents of spinal cord injury and 10 million of TBI per year (WHO). Most of these diseases have no effective therapy yet. It is expected that EVs products will be effective in the niche indications of above-mentioned conditions preventing neuroinflammatory-related damage of central nervous system. Moreover, EVs will be able to target an acute diseases i.e. TBI, brain stroke, spinal cord injury, more effectively when comparing to allogenic MSCs, due to the EV’s stability and easier administration at shorter time what is critical for successful therapy. The latter would additionally expand a potential market of EVs products beyond the competitive allogenic MSCs products.

Epilepsy is one of the most common brain diseases affecting about 1 in 100 children under 17-year old according to CDC. Epilepsy carries significant detrimental effects on the quality of life and can lead to a secondary brain damage. The disease can have different aetiology, including stroke, brain trauma, and neuro-inflammation. Severity of the seizures is variable and the antiepileptic drugs are effective only in about 2/3 of the patients.
Vitavita
0
Vervolg:
About the consortium partners:

Ospedale Pediatrico Bambino Gesu´ OPBG (Rome, Italy) is the largest paediatric Hospital and research center in Europe, providing over 1.550.000 healthcare services each year to children and adolescents from all over the world. OPBG pursues excellency in health care through advanced research and clinical activities, while improving processes to exploit the progress of biomedical science. The Hospital’s clinical activities run side by side with its sci- entific research, aiming at constantly improving and innovating diagnostic and therapeutic procedures. OPBG’s Research Laboratories are located in a 5,000 sqm research facility, fully equipped with high-tech systems, supporting genomics, metagenomics, metabolomics, pro- teomics, microarray technology, cytogenetic and FISH applications, cytofluorimetry and cell sorting, cell and molecular biology. Within the Research Laboratories the team led by the Immunologist Dr Alessandra Fierabracci has established potency assays for evaluating the immunomodulatory activity of MSC-derived exosomes in vitro.

The IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri” (www.marionegri.it) in Milan, Italy is a non-profit biomedical research institute. The Institute’s constant research areas include cardiovascular, psychiatric and neurological diseases, and tumours. Over the years, in line with technical advances, research has spread into the fields of environment and health, kidney diseases, organ transplantation, and rare diseases,

The Institute works regularly with various associations, hospital groups with different specialties, general practitioners, and nurses, setting up nation-wide cooperation networks. Underlying all this is basic research in pharmacokinetics, pharmacology, immunology, cell biology, genomics, proteomics, and metabolomics; it organizes controlled randomized clinical trials, studies on cohorts of elderly people, systemic reviews and meta-analyses.

Dr Annamaria Vezzani is Head of the Laboratory Experimental Neurology, Dept of Neuroscience, and she will be contributing to the project by sharing her long standing expertise with animal models of epilepsy and neuroinflammation to test the therapeutic anticonvulsive potential of extracellular vesicles and provide proof-of-concept evidence for clinical applications.

The department of Woman’s and Child’s Heath of the University of Padua is a 269-bed tertiary paediatric academic care centre, serving the entire North East region of Italy, devoted to provide excellence in patient’s care, teaching and research, also including a ten-store research building. It is one of the eleven fully recognised Italian Children’s Hospitals.

The University of Padova was founded in 1222. It includes 32 Departments, 1 University Hospital, 1 Veterinary Hospital, 1 Experimental Farm, 1 School of Excellence. It counts 61,000 Students and 12,000 Graduates per year.
Vitavita
0
Uitgelicht:

.....
Led by Professor Federico Vigevano at Bambino Gesu` Children’s Hospital with Dr Alessandra Fierabracci providing her expertise in Immunology and Dr. Annamaria Vezzani at Mario Negri Institute, pre-clinical tests of mesenchymal stem cells (MSC)-derived EVs are underway to confirm the safety and efficacy already demonstrated in multiple in vitro and in vivo models. This project will enable the first-in-man use of MSC-derived EVs and exosomes in treatment of drug-resistant epilepsy in children. The project follows a long-term collaboration between the Children’s Hospital and the Esperite group initiated and liaised by Professor Stefano Grossi, Esperite’s Scientific Director in Italy.
......
Vitavita
0
Esperite geeft aan dat er een nieuw productielijn in de maak is, waarbij Esperite de capaciteit en kwaliteit ( mede door inbreng van de genoemde medici) kan leveren in deze nieuwe bio-industrie:

... The consortium will also investigate EVs and exosomes characteristics, potency, and a mode of action and will further improve the EVs production processes...
... The Cell Factory, in partnership with Professor Maurizio Muraca's team at University of Padua, are better characterising EVs to establish clinical grade standards for production, purification, quantification, bio-distribution and molecular characterisation of new EV-based therapeutics....
... Professor Muraca has also agreed to join the Scientific Board of The Cell Factory to support EVs products development and clinical translation...
... The Cell Factory produces ultra-pure EVs and exosomes according to GLP/GMP guidelines, using proprietary technology for expansion of MSC in fully defined media with no use of animal-derived components at any stage. Stem cells expansion is performed in the most efficient and scalable 3D culture systems using microcarrier beads. The Cell Factory's proprietary closed cell culture system produces high purity EVs and exosomes using pharmaceutical-quality sequential filtration system for EVs extraction and purification. The system can be easily scaled up improving significantly EVs production costs, footprint and process scalability. EVs products can be manufactured with this technology at least 10x more efficiently and cheaper when comparing to MSC equivalent...

Wordt later dit weekend vervolgd bij immunologie draadje .
Vitavita
0
Tigenix richt zich op:

"....is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.

Esperite (The Cell Factory) richt zich al op de volgende technologische ontwikkeling:

"..Moreover, EVs will be able to target an acute diseases i.e. TBI, brain stroke, spinal cord injury, more effectively when comparing to allogenic MSCs, due to the EV’s stability and easier administration at shorter time what is critical for successful therapy. The latter would additionally expand a potential market of EVs products beyond the competitive allogenic MSCs products."

Inclusief:
"Extracellular vesicles (EVs) disruptive technology targets unmet needs in neuroinflammatory diseases at lower costs than allogenic stem cell therapies."
Vitavita
0
Professor Federico Vigevano, belangrijke inetrantioanle onderscheiding in september 2016 voor klinische en wetenschappelijke activiteiten m.b.t.epilepsie. translate.google.nl/translate?hl=nl&a...

Maurizio Muraca en Alessandra Fierabracci zijn de schrijvers/uitvinders van de 2 aangekochte patenten in 2015.

Annamaria Vezzani Research Immunity and Inflammation in Epilepsy
Vitavita
0
quote:

Vitavita schreef op 2 oktober 2016 15:41:

Professor Federico Vigevano, belangrijke inetrantioanle onderscheiding in september 2016 voor klinische en wetenschappelijke activiteiten m.b.t.epilepsie. translate.google.nl/translate?hl=nl&a...

Maurizio Muraca en Alessandra Fierabracci zijn de schrijvers/uitvinders van de 2 aangekochte patenten in 2015.

Annamaria Vezzani Research Immunity and Inflammation in Epilepsy

ahum, inetrantioanle = internationale.....

letters op een rijtje zetten ;-)
257 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
860,01  -5,35  -0,62%  19 apr
 Germany40^ 17.714,20 -0,69%
 BEL 20 3.827,75 +0,03%
 Europe50^ 4.904,14 -0,28%
 US30^ 37.851,00 0,00%
 Nasd100^ 17.004,48 0,00%
 US500^ 4.960,72 0,00%
 Japan225^ 37.028,48 0,00%
 Gold spot 2.392,50 0,00%
 EUR/USD 1,0655 +0,11%
 WTI 82,10 0,00%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

WDP +3,12%
Kendrion +2,92%
EBUSCO HOLDING +2,67%
Vopak +2,61%
NX FILTRATION +2,17%

Dalers

JUST EAT TAKE... -5,11%
TomTom -4,68%
Fugro -4,30%
ASMI -4,00%
BESI -3,64%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront